GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » Cyclically Adjusted Book per Share

Halozyme Therapeutics (FRA:RV7) Cyclically Adjusted Book per Share : €0.98 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Halozyme Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was €1.286. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.98 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted Book Growth Rate was 15.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 17.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 19.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Halozyme Therapeutics was 31.00% per year. The lowest was -5.30% per year. And the median was 13.75% per year.

As of today (2024-06-14), Halozyme Therapeutics's current stock price is €46.08. Halozyme Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.98. Halozyme Therapeutics's Cyclically Adjusted PB Ratio of today is 47.02.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Halozyme Therapeutics was 79.11. The lowest was 19.84. And the median was 43.42.


Halozyme Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Halozyme Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Cyclically Adjusted Book per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.50 0.68 0.84 0.93

Halozyme Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.84 0.97 0.93 0.98

Competitive Comparison of Halozyme Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PB Ratio falls into.



Halozyme Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Halozyme Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.286/131.7762*131.7762
=1.286

Current CPI (Mar. 2024) = 131.7762.

Halozyme Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.325 100.560 0.426
201409 0.247 100.428 0.324
201412 0.267 99.070 0.355
201503 0.273 99.621 0.361
201506 0.350 100.684 0.458
201509 0.222 100.392 0.291
201512 0.308 99.792 0.407
201603 0.205 100.470 0.269
201606 0.068 101.688 0.088
201609 -0.083 101.861 -0.107
201612 -0.238 101.863 -0.308
201703 -0.421 102.862 -0.539
201706 0.365 103.349 0.465
201709 0.427 104.136 0.540
201712 1.233 104.011 1.562
201803 1.494 105.290 1.870
201806 1.513 106.317 1.875
201809 1.422 106.507 1.759
201812 1.512 105.998 1.880
201903 1.583 107.251 1.945
201906 1.578 108.070 1.924
201909 1.521 108.329 1.850
201912 0.604 108.420 0.734
202003 0.388 108.902 0.469
202006 0.686 108.767 0.831
202009 0.621 109.815 0.745
202012 0.920 109.897 1.103
202103 0.396 111.754 0.467
202106 0.699 114.631 0.804
202109 1.698 115.734 1.933
202112 1.268 117.630 1.420
202203 1.714 121.301 1.862
202206 2.014 125.017 2.123
202209 0.725 125.227 0.763
202212 1.186 125.222 1.248
202303 0.467 127.348 0.483
202306 1.057 128.729 1.082
202309 1.768 129.860 1.794
202312 0.606 129.419 0.617
202403 1.286 131.776 1.286

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Halozyme Therapeutics  (FRA:RV7) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Halozyme Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=46.08/0.98
=47.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Halozyme Therapeutics was 79.11. The lowest was 19.84. And the median was 43.42.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Halozyme Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics (FRA:RV7) Business Description

Industry
Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (FRA:RV7) Headlines

No Headlines